EUVIMEDEUVIMED entdecken
Crossref

Diagnostic and Prognostic Value of Combined Detection of Serum Protein Induced by Vitamin K Absence or Antagonist-II, Alpha-Fetoprotein, and Spliced Hepatitis B Virus in Hepatitis B Virus-Induced Hepatocellular Carcinoma

Zhentian Guo, Haixing Mo, Yuqing Yuan, Wenjin Fu iD

Cancer Biotherapy and Radiopharmaceuticals · 2025

DOI: 10.1089/cbr.2025.0085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2025. Verfasst von Zhentian Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Clinical School of Guangdong Medical University, Zhanjiang, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, alpha-Fetoproteins, Hepatitis B virus. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To demonstrate the diagnostic and prognostic value of combined detection of serum abnormal prothrombin II (PIVKA II), α-fetoprotein (AFP), and spliced variants of hepatitis B virus genomes (spHBV) in HBV-induced hepatocellular carcinoma (HCC). Materials and Methods: From March 2018 to May 2019, samples were collected from 125 patients with HBV-related hepatocellular carcinoma (HBV-HCC), 125 patients with pure HBV (HBV group), and 125 patients with HBV-induced cirrhosis (HBV cirrhosis group), all of whom were receiving treatment at the hospital. Serum levels of PIVKA-II, AFP, and spHBV were measured using an immunochemiluminescence detection system, a fully automated immunoassay analyzer, and a real-time quantitative polymerase chain reaction instrument, respectively. Kaplan–Meier method was applied to analyze relationship among serum PIVKA-II, AFP, spHBV, and prognosis of patients with HBV-HCC; cyclooxygenase (COX) risk regression analyzed factors affecting prognosis of patients with HBV-HCC; receiver operating characteristic (ROC) curve evaluated diagnostic and prognostic predictive efficacy of serum PIVKA-II, AFP, and spHBV alone or combined for HBV-HCC.

Results

The serum concentrations of PIVKA-II, AFP, and spHBV in the HBV-HCC group were significantly higher than those in the HBV cirrhosis group and the HBV group (all p < 0.05). The HBV cirrhosis group also showed significantly higher levels compared with the HBV group ( p < 0.05). Serum PIVKA-II, AFP, spHBV, tumor number, tumor-node-metastasis (TNM) stage, and extrahepatic metastasis differed markedly between dead patients and surviving patients ( p < 0.05). PIVKA-II, AFP, and spHBV in patients with HBV-HCC were related to tumor number, TNM staging, and extrahepatic metastasis ( p < 0.05).The 36-month survival rate of patients with high-expression PIVKA-II was inferior to patients with low expression ( χ 2 = 6.561, p = 0.010); the 36-month survival rate of patients with high-expression AFP was inferior to patients with low expression ( χ 2 = 4.789, p = 0.029); and the 36-month survival rate of patients with high-expression spHBV was inferior to patients with low expression ( χ 2 = 5.761, p = 0.016). Multivariate logistic regression analysis showed that high expression of PIVKA-II, AFP, spHBV in serum, multiple tumors, TNM staging of stage III–IV, and extrahepatic metastasis were all risk factors for death in patients with HBV-HCC ( p < 0.05). The area under the curve (AUC) of the combination of serum PIVKA-II, AFP, and spHBV in the diagnosis for HBV-HCC was markedly higher than PIVKA-II, AFP, and spHBV alone diagnosis ( p < 0.05). The AUC predicted by the combination of serum PIVKA-II, AFP, and spHBV in predicting the prognosis of patients with HBV-HCC was markedly higher than that predicted by the three factors alone ( p < 0.05).

Conclusions

Serum PIVKA-II, AFP, and spHBV joint detection has significant clinical value for diagnosis and prognosis of HBV-HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsHepatitis B virusProthrombinProtein PrecursorsBiomarkersBiomarkers, TumorHepatitis BHumansMaleFemaleMiddle AgedPrognosisAdultAged

Stichwörter der Autor:innen

HBVabnormal prothrombindiagnosishepatocellular carcinomaprognosisspliced variants of HBV genomesα-fetoprotein

Substanzen

alpha-FetoproteinsacarboxyprothrombinProthrombinProtein PrecursorsBiomarkersBiomarkers, TumorAFP protein, human

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Clinical School of Guangdong Medical University, Zhanjiang, China.
  • Department of Laboratory Medicine, The Tenth Affiliated Hospital of Southern Medical University(Dongguan People's Hospital), Dongguan, China.
  • The First Clinical School of Guangdong Medical University, Zhanjiang, China.
  • Department of Laboratory Medicine, Guangdong Medical University Affiliated Dongguan Houjie Hospital, Dongguan, China.

ORCID-Profile: Wenjin Fu

Zitieren

APA

Guo, Z., Mo, H., Yuan, Y., & Fu, W. (2025). Diagnostic and Prognostic Value of Combined Detection of Serum Protein Induced by Vitamin K Absence or Antagonist-II, Alpha-Fetoprotein, and Spliced Hepatitis B Virus in Hepatitis B Virus-Induced Hepatocellular Carcinoma. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2025.0085

Vancouver

Guo Z, Mo H, Yuan Y, Fu W. Diagnostic and Prognostic Value of Combined Detection of Serum Protein Induced by Vitamin K Absence or Antagonist-II, Alpha-Fetoprotein, and Spliced Hepatitis B Virus in Hepatitis B Virus-Induced Hepatocellular Carcinoma. Cancer Biotherapy and Radiopharmaceuticals. 2025. doi:10.1089/cbr.2025.0085

BibTeX
@article{Guo2025,
  author = {Guo, Zhentian and Mo, Haixing and Yuan, Yuqing and Fu, Wenjin},
  title = {Diagnostic and Prognostic Value of Combined Detection of Serum Protein Induced by Vitamin K Absence or Antagonist-II, Alpha-Fetoprotein, and Spliced Hepatitis B Virus in Hepatitis B Virus-Induced Hepatocellular Carcinoma},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2025},
  doi = {10.1089/cbr.2025.0085}
}
Kostenlos starten →